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from 8.98 o 1.44% to 7.91 o 1.19% , decrease in BMI 0.26 o 1,36 kg/m2 and reduc-
tion in major and minor hypoglycemic events by 97% and 80% respectively. Proba-
bilities of complications, management costs adjustments (including complications) 
were derived from the Czech surveys from 2007. Treatment costs were from June 
2009. Future costs and clinical beneﬁts were discounted at 3.5 % per annum. 
RESULTS: The short-term beneﬁts of switching from BHI 30 to BIAsp 30 are pro-
jected to lead to an increase in discounted quality-adjusted life expectancy of 0.493 
years (4191 o 0.090 versus 3698 o 0.078). Increased total lifetime costs/patient is -
CZK122,594 (534,259 o 1,9925 versus 65,7212 o 21,908) with BIAsp 30. Combining 
costs and clinical outcomes results in an incremental cost-effectiveness per quality-
adjusted life year (QALYs) gained were dominant. CONCLUSIONS: CORE diabetes 
T2 patients sub-cohort simulation in 35 years perspective Czech observational study 
has demonstrated acceptable cost-effectiveness for patients with type 2 diabetes treated 
BIAsp 30. BIAsp 30 treatment was projected to be associated with improvements in 
life expectancy, QALYs and cost saving compared to BHI 30. Sensitivity analyses show 
cost-effectiveness result to be robust.
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OBJECTIVES: Imbalanced levels of parathyroid hormone (PTH), serum calcium (Ca) 
and phosphorus (P) are associated with an increased risk of cardiovascular death and 
fracture. Cinacalcet can regulate these levels in patients with SHPT. Here we describe 
a cost-utility analysis of cinacalcet treatment in SHPT patients in Italy. METHODS: 
We developed a probabilistic patient-level simulation Markov model to simulate the 
effect of cinacalcet on individual Ca, P, and PTH levels (based on data of a European 
multicenter, open-label study); to correlate these levels with mortality and morbidity 
(cardiovascular events, fractures, and parathyroidectomies) recently published in two 
reviews; and to incorporate Italian data for dialysis patients and national cost struc-
ture. Simulation horizon was patient lifetime; simulated treatment alternatives were 
standard treatment (mainly vitamin D sterols and phosphate binders), and cinacalcet 
plus standard treatment. A 3.5% discount rate was applied to life expectancy (LE), 
quality-adjusted life expectancy (QALE), and costs and times in ranges (TiRs) recom-
mended by the KDOQI initiative. Utilities were derived from a prospective cross sec-
tional survey of 180 end-stage renal failure patients with and without co-morbidities. 
Costs were evaluated from the Italian National Healthcare Service perspective. 
RESULTS: Base case results were calculated with 10,000 iterations. Cinacalcet-treated 
patients had a mean (SD) increase in TiR of 5.60 (6.57), 3.45 (6.85), 1.62 (5.64) and 
2.85 (5.60) discounted patient years for PTH, Ca, P, and all parameters, respectively. 
Mean LE extension was 1.16 (3.74) life-years and QALE increase 0.77 (2.63). The 
incremental cost-effectiveness ratio (ICER) calculated considering the TiR varied from 
a5,439 per patient-year in range to a18,748 per patient-year in range (limits for PTH 
and P, respectively). When considering LE, the average ICER results were a26,148/LY 
while when considering QALE, the average ICER was a39,454/quality-adjusted life 
year. CONCLUSIONS: Cinacalcet treatment could be considered cost-effective but 
further investigation is needed.
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OBJECTIVES: To investigate the health economics outcomes of insulin glargine (GLA) 
usage in comparison with insulin NPH (NPH) in diabetes type-2 (DM 2) in real 
practice in the Russian Federation. METHODS: Observational study has been per-
formed in 92 centers in 35 cities of Russia. Two goups of patients (1st- 100 pts received 
GLA o.d, 2d—100 pts—NPH bid) were analized for 6-months period. Group GLA 
had been switched previously from NPH. Efﬁcacy was evaluated according to HbA1ñ 
level as target a7%. The performed CEA analysis included direct costs of medications 
based on average dosages, hospitalizations, days of disability and hypoglycemias. 
RESULTS: The duration of DM 2 was equal in both groups—above 9 years. In 
GLA—87% pts and in 92% NPH pts had high HbA1c at baseline, and 45% and 82% 
(p  0.001) after the end of the study accordingly. Average daily doses of GLA at the 
end of the study were 32.9 UI and for NPH—34,1 UI. Hospitalization rate was higher 
in NPH than in GLA (1,44 vs 0,73 day/patient, p  0.01), disability days (1,37 vs 
0,82 days, p  0.05). The CER was better for GLA vs NPH—a314 RUR and 780 
RUR accordingly. Increase of additional cost was higher for NPH (23.71%) than for 
GLA (7.78%) per patient. CONCLUSIONS: GLA in DM 2 is more cost-effective in 
comparison with NPH due to a better efﬁcacy and safety.
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OBJECTIVES: Type-2 diabetes mellitus (T2DM) is a progressive chronic disease 
placing a huge clinical and ﬁnancial burden on health care services. A recent random-
ized open-label clinical trial (NCT00082381) comparing exenatide with insulin 
glargine provided evidence of the short-term clinical proﬁle of exenatide. The objective 
of this cost-effectiveness analysis was to use these results as the basis for long-term 
projections to estimate the clinical and cost outcomes associated with exenatide treat-
ment versus insulin glargine over a 15-year time horizon in a Turkish setting. 
METHODS: The analysis used the previously published and validated IMS Core 
Diabetes Model, comprised of a series of Markov-based submodels simulating the 
major complications of diabetes (cardiovascular, renal, eye and neurological disease). 
Using baseline characteristics (mean age 58.9 years; 55.7% male; mean HbA1c 8.21%; 
mean duration of diabetes 9.56 years), complications and concomitant medications 
from study NCT00082381, analysis was performed using a non-parametric bootstrap-      
ping approach where disease progression was simulated to estimate costs, life expect-
ancy and quality-adjusted life expectancy (QALE). RESULTS: Exenatide treatment 
was projected to improve life expectancy (mean[SD] years: 8.41[0.09]) and QALE 
(mean[SD] quality-adjusted life years [QALY]: 6.00[0.07]) compared with insulin 
glargine (mean[SD] years: 8.38[0.08]; mean[SD] QALY: 5.62[0.06]), while also delay-
ing the onset of diabetes-related complications (years to onset: exenatide: 4.04; insulin 
glargine: 4.00). Lifetime direct medical costs were higher for exenatide with a 
mean(SD) of 53,573(819) New Turkish Lira (YTL) compared with insulin glargine 
YTL 42,361(770). The incremental cost-effectiveness ratio (ICER) based on QALE 
for exenatide was YTL 30,018 per QALY gained versus insulin glargine. CONCLU-
SIONS: The outcome of this analysis was that exenatide treatment was projected to 
improve life expectancy and QALE and reduce cumulative incidence of most diabetes-
related complications including cardiovascular disease, compared with insulin glargine. 
By current Turkish standards, the ICER for exenatide would be considered to repre-
sent good value for money.
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OBJECTIVES: To estimate the cost-utility of vildagliptin in the treatment of diabetes 
mellitus type 2, in combination with metformin, compared to the standard strategy        
of treatment in Poland: combination of metformin and sulphonylure.       METHODS: 
The cost-utility analysis is based on Markov decision model (package Tree Age Pro        
2008). The following strategies of treatment were compared: vildagliptin (50 mg twice     
daily) versus glimepiride (mean dose 4,5 mg/day) both added to metformin (mean dose            
1892 mg/day). Direct medical costs were considered: cost of oral antidiabetic drugs          
(OAD), cost of insulin, additional costs of treatment of type 2 diabetes (e.g. test strips, 
lancets), cost of general practitioner, cost of specialist visits, cost of complications of         
type 2 diabetes mellitus treatment. Polish cost data was used. The units of effectiveness    
in the analysis were quality adjusted life years (QALY) and life years gained (LYG). 
The outcome of the analysis was incremental cost-effectiveness ratio (ICER), which 
presents the cost of gaining one additional unit of QALY or LYG in the case of using 
therapy with vildagliptin instead of the comparator. Data concerning clinical effective-
ness of compared interventions and also of other strategies of treatment (used after 
OAD treatment) were taken from RCT studies, long term studies and systematic 
reviews. The target population consisted of adult patients with diagnosed diabetes 
mellitus type 2, inadequately controlled with metformin in monotherapy. Both payer’s  
perspective (National Health Fund and patient) and a lifelong time horizon were 
assumed in the analysis. RESULTS: Cost of gaining one additional unit of QALY 
and one additional unit of LYG in the case of using combination therapy 
vildagliptinmetformin instead of therapy glimepiridemetformin is 58,483 PLN and 
589,575 PLN, respectively. CONCLUSIONS: Assuming the Polish acceptable thresh- 
old which is 91,914 PLN, treatment with combination of vildagliptin and metformin           
is cost-effective.
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OBJECTIVES: Diabetic nephropathy is a frequent and serious complication in patients 
with type-2 diabetes mellitus (DM), and it is the most frequent cause of End Stage 
Renal Disease (ESRD) in industrialized countries. The global incidence of ESRD con-
tinues to rise, and ESRD patients requires intensive and costly treatments such as 
dialysis or transplantation; thus, the burden of illness is growing and the resources 
allocated to treatment are increasing. The objective of our study was to evaluate the 
economic impact of losartan added to the standard care administered to diabetic 
subjects with End-Stage Renal Disease in Italy. METHODS: We conducted a cost-
effectiveness analysis comparing the economic and clinical outcomes deriving from the 
administration of additional losartan to standard care versus standard care alone in 
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patients with type 2 diabetes and nephropathy over 3.4 years. The clinical outcome 
data were based on the results from the RENAAL trial. Direct medical costs referred 
to the purchase costs of losartan and the cost of National Health Service (NHS) hos-
pitalization. The costs were discounted back at an annual rate of 3%. Also sensitivity 
analysis was performed. RESULTS: RENAAL study establishes that losartan, along 
with conventional antihypertensive treatment as needed, confers strong renal protec-
tion in patients with type-2 diabetes and nephropathy. Globally, the total cost over 
42 months of follow-up was estimated at 9.802,49 a in the losartan and a13,405,47 
in the placebo group, resulting into a cost saving of a3602.98 per patient. Results 
were robust to both clinical and economic variables. CONCLUSIONS: In addition to 
the medical beneﬁt, this analysis demonstrated the economic relevance of treatment 
with losartan in type 2 diabetic patients with nephropathy.
PDB30
CSII COMPARED TO MDI: A HEALTH ECONOMIC ANALYSIS IN THE 
GERMAN HEALTH CARE SETTING
Neeser K, Kocher S, Weber C, Heister F
Institute for Medical Informatics and Biostatistics, Basel, Switzerland
OBJECTIVES: A recently published health technology appraisal (NICE guidance 57) 
on continuous subcutaneous insulin infusion (CSII) therapy considered observational 
studies to complement RCTs in the assessment of effectiveness of CSII in type 1 dia-
betes patients. Observational studies showed signiﬁcantly higher improvements in       
HbA1c levels with CSII compared to multiple daily injections (MDI) as available RCTs       
did. Furthermore, a statistically signiﬁcant decrease of severe hypoglycaemic episodes 
has been stated. Our model based analysis assessed the clinical and economical impact          
in Germany. METHODS: The following baseline assumptions were applied within 
our validated type 1 diabetes model: (1) patient characteristics at simulation start (age 
26 years, duration of diabetes 12 years, baseline HbA1c 8.7%,); (2) a HbA1c improve-
ment by CSII compared to MDI of 0.6% (RCTs) and 1.2% (observational); (3) 
reduction of severe hypoglycemic events by 50%; (4) costs for insulin pumps a3,680 
during an amortization period of 4 years; (5) annual costs for infusion sets a1,040. 
RESULTS: With CSII total life time costs per patient increased by a50,967 / a36,873 
with an HbA1c reduction of 0.6% / 1.2%. Life expectancy increased by 0.99 / 2.00 
years, respectively. In consequence RCTs yield to an incremental cost-effectiveness 
ratio (ICER) of a51,736 and observational studies to a18,359 per life year gained. 
Life time cumulated costs for nephropathy and amputation with CSII compared 
to MDI decreased by a10,787 / a22,967 and a1,183 / a2,462, respectively. 
CONCLUSIONS: The NICE appraisal judged observational data in CSII as better 
resembling the population in routine care. Data derived from observational studies 
indicate that HbA1c-reductions can be distinctly higher than described in RCTs. In 
consequence the ICER could improve considerably. In the underlying analysis the 
additional costs for insulin pump and consumables are partially compensated by the 
reduced complication-related costs due to the improved glycemic control in CSII 
therapy.
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OBJECTIVES: A multicentre, randomised, double-blind, placebo-controlled clinical 
trial was conducted in Japanese impaired glucose tolerance (IGT) population to evalu-
ate the effect of preventing the development of type-2 diabetes mellitus (T2DM), and 
a signiﬁcant effect of voglibose in preventing the development of T2DM was conﬁrmed 
compared to the placebo. The objective of this analysis was to estimate the cost-
 effectiveness of administering voglibose in addition to standard care of diet and exer-
cise compared to standard care alone for high-risk Japanese individuals with IGT. 
METHODS: An annual cycle Markov model was constructed to estimate the long-
term prognosis of individuals with IGT (56-years-old), in terms of expected medical 
costs, and life expectancy. The Markov model consisted of ﬁve stages: normal glucose 
tolerance, IGT, T2DM, dialysis and death. Transition probabilities were derived from 
the results of the voglibose clinical trial as well as the epidemiological information. 
Costs included the drug acquisition cost of voglibose, IGT management cost, annual 
medical costs of T2DM and cost of dialysis. Effectiveness was evaluated by life expec-
tancy. The future costs and effectiveness were discounted by 3% per year. RESULTS: 
Expected lifetime costs for the voglibose administration group and the standard care 
group were calculated at JPY718,724 (a5,380) and JPY1,365,405 (a10,220) respec-
tively, with voglibose administration resulting in an estimated saving of JPY646,681 
(a4,840). Life expectancy was calculated at 18.672 years and 18.073 years respec-
tively, with life expectancy prolonged by 0.599 years when voglibose was administered 
along with the standard care. CONCLUSIONS: In order to prevent T2DM among 
Japanese individuals with IGT, intervention by voglibose together with the standard 
care for life-style modiﬁcation resulted in the expectation of long-term cost-saving, as 
well as prolongation of life expectancy, compared to the standard care of conducting 
only diet and exercise therapies.
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OBJECTIVES: CHD, DMT2 and COPD constitute an enormous burden of disease 
due to high prevalence, severe co-morbidities, increased mortality and high costs for 
society. Smoking is a main risk factor for developing the mentioned diseases and has 
a major impact on the disease development. Aim of the presented study was to analyze 
the incremental cost-effectiveness ratios (ICER) of smoking cessation with NRT com-
pared to Placebo/no intervention for patients with CHD, DMT2 and COPD. 
METHODS: The ICERs were calculated for each study population by use of separate 
Markov-Models. Patient started the models in the age of 45 years and undertake a 
single quit attempt with NRT or Placebo/no intervention. According to the likelihood 
of success, the diseases’ long-term natural courses are simulated for either smokers or 
ex-smokers. Input data such as success rate of smoking quit attempt, transition prob-
abilities, costs (base year 2008) are based on systematic literature researches and 
internal calculations. From the perspective of the German Statutory Health System, 
incremental costs per life-year gained (LYG) are calculated. Assumptions and uncer-
tain parameters are set conservatively and tested in multiple sensitivity analyses. 
RESULTS: Within a simulated time horizon of 55 years, smoking cessation with NRT 
is the dominant strategy: in all indications, NRT leads to additional LYGs at lower 
costs compared to Placebo/no intervention. NRT remains the dominant strategy 
throughout most sensitivity analyses. The parameters of highest inﬂuence on the 
outcome are the effectiveness of both strategies and additionally considered costs for 
smokers. CONCLUSIONS: NRT is a cost-effective treatment option for smoking 
cessation compared to Placebo or no intervention in patients with CHD, diabetes and 
COPD. The results of these analyses are robust to the variation of numerous model 
parameters and assumptions.
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OBJECTIVES: To project long term costs and outcomes for continuous subcutaneous         
insulin infusion (CSII) compared with multiple daily injections (MDI) of insulin in 
adult type-1 diabetes mellitus (T1DM) patients in Italy from the National Health 
Service (NHS) perspective. METHODS: The CORE Diabetes Model (CDM) was used 
to determine the incremental cost-effectiveness ratio (ICER) of CSII compared with 
MDI among adult patients with T1DM in Italy. The primary input variable was 
change in HbA1c and assumed to be a 1.2% improvement for CSII as compared to 
MDI in a cohort of Italian T1DM patients with an average HbA1c baseline value of 
8.95%. It was also assumed that CSII patients had 50% less hypoglycemic events 
compared with MDI patients. A series of Markov constructs simulated the progression 
of diabetes-related complications. The average annual cost for CSII and MDI were 
a5699.20 and a2734.71, respectively. The costs were derived from Italian-speciﬁc 
sources and other published data. A 60-year time horizon and a discount rate of 3.0% 
per annum on costs and clinical outcomes were used. RESULTS: Treatment with CSII 
was associated with improvements in life expectancy of 0.981 years vs. MDI and 
quality adjusted life year (QALY) of 1.063 years vs. MDI with corresponding ICERs 
of a34,541 per life-year and a31,879 per quality-adjusted life year (QALY) gained for 
CSII compared with MDI. The cumulative incidence of end-stage renal disease (ESRD) 
was reduced by 18% (RR  0.816) with a NNT of 22 patients to avoid one case of 
ESRD.while cumulative incidence of peripheral vascular disease (PVD) was reduced 
by 14% (RR  0.856); with a NNT of 46 patients to avoid one case of PVD. CON-
CLUSIONS: Setting the willingness to pay at a40,000/QALY (based on a £30,000 
NICE threshold), CSII is a cost-effective treatment option when compared to MDI for 
adult patients with T1DM in Italy.
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OBJECTIVES: To compare the direct treatment costs in insulin-naïve type-2-diabetics 
(T2D) starting a basal supported oral therapy (BOT) with either insulin glargine (GLA) 
or NPH-insulin (NPH) over 10 years focusing on the different persistence to these 
regimens. METHODS: A cost-minimization approach was applied. The analysis was 
conducted from the German statutory health insurance (SHI) perspective. A Markov 
model was developed simulating the onset of a BOT with GLA or NPH at a ratio of 
1:1 and thereafter switching to an intensiﬁed conventional therapy (ICT) with the 
same basal insulin in the course of 10 years. Persistence data were obtained from the 
IMS Disease Analyzer database [1] considering the ﬁrst 6 months after starting BOT 
as titration phase. Cost data were derived from a German cost evaluation in an 
